Aprea Therapeutics (Aprea Therapeutics) Equity-to-Asset : 0.75 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aprea Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $16.95 Mil. Aprea Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $22.65 Mil.

The historical rank and industry rank for Aprea Therapeutics's Equity-to-Asset or its related term are showing as below:

APRE' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.44 Med: 0.83 Max: 0.93
Current: 0.75

During the past 7 years, the highest Equity to Asset Ratio of Aprea Therapeutics was 0.93. The lowest was -1.44. And the median was 0.83.

APRE's Equity-to-Asset is ranked better than
60.38% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs APRE: 0.75

Aprea Therapeutics Equity-to-Asset Historical Data

The historical data trend for Aprea Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics Equity-to-Asset Chart

Aprea Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.93

0.83

0.87

0.85

0.75

Aprea Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.85	0.83	0.82	0.79	0.75

Competitive Comparison of Aprea Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Aprea Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprea Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's Equity-to-Asset falls into.

Aprea Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Aprea Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	16.954	/	22.65
	=

Aprea Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	16.954	/	22.65
	=

Aprea Therapeutics (NAS:APRE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Aprea Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprea Therapeutics (Aprea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3805 Old Easton Road, Doylestown, PA, USA, 18902

Website

https://www.aprea.com

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Executives

Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill	officer: SrVP/CFO/Prin. Fin &Acctg. Off	4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger	director	C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey	director	27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad	officer: President, CEO	535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu	director	535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade	director, officer: President & CEO	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar	officer: SVP, Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel	officer: Chief Business Officer	535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen	officer: SVP, Chief Scientific Officer	535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107